TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Profound Medical ( (TSE:PRN)) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first commercial, non-trial prostate cancer treatment using the ...
Hosted on MSN
Profound Medical targets 70–75% revenue growth in 2025 as TULSA-AI and CAPTAIN trial progress fuel confidence
CEO Arun Swarup Menawat summarized that "our sales team has been stabilized. That, combined with our large and growing TULSA-PRO pipeline, continues to drive our confidence in our ability to deliver ...
TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...
Transurethral ultrasound ablation (TULSA) procedures are performed using the TULSA-PRO system when treating people who have prostate disease, including an enlarged prostate and prostate cancer. There ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results